Metabolic acidosis: Difference between revisions

Content deleted Content added
remove derivation which pulls numbers out of nowhere and has no clear point; restore ideas from 2006
Tag: Reverted
dash style (MOS:DASH), range style, make use of abbreviations, standardize capitalization, non-breaking space use (MOS:NBSP)
(5 intermediate revisions by 2 users not shown)
Line 1:
{{Infobox medical condition (new)
| name = Metabolic acidosis
| synonyms =
| image = Bicarbonate Levels in Metabolic Acidosis.jpg
| caption = The calculated level of bicarbonate in the blood (HCO<sub>3</sub><sup>−</sup>) reflects the severity of acidosis.
| pronounce =
| field = [[Nephrology]]
| types = Acute Metabolic Acidosis<br>
Chronic Metabolic Acidosis
| symptoms =
| complications = '''Acute:''' poor morbidity and mortality outcomes;<br>
'''Chronic:''' adverse outcomes on kidney function, musculoskeletal system, possible cardiovascular effects
| onset =
| duration =
| causes = '''Acute:''' Excessive amounts of organic acids;<br>
'''Chronic:''' Impaired kidney function
| risks =
| diagnosis = Level of bicarbonate (HCO3-) in the blood
| differential =
| prevention =
| treatment = '''Acute:''' Mitigation of the underlying cause for the metabolic problem, such as administration of insulin in cases of diabetic ketoacidosis or restoration of effective circulating intravascular volume in cases of lactic acidosis. The administration of IV bicarbonate, although intellectually appealing, is rarely indicated or administered
'''Chronic:''' Diet rich in fruits and vegetables, oral alkali therapy<ref>{{cite journal |last1=Navaneethan |first1=Sankar D. |last2=Shao |first2=Jun |last3=Buysse |first3=Jerry |last4=Bushinsky |first4=David A. |title=Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis |journal=Clinical Journal of the American Society of Nephrology |volume=14 |issue=7 |pages=1011–1020 |language=en |doi=10.2215/CJN.13091118 |pmid=31196951 |pmc=6625635 |date=5 July 2019}}</ref>
| medication =
| prognosis =
| frequency = '''Acute:''' Most often presented during critical illnesses, and hospitalizations: incidence ranging from 14-4214–42%.<ref name="Treatment of acute metabolic acidos">{{cite journal |last1=Kraut |first1=Jeffrey A. |last2=Madias |first2=Nicolaos E. |title=Treatment of acute metabolic acidosis: a pathophysiologic approach |journal=Nature Reviews Nephrology |date=4 September 2012 |volume=8 |issue=10 |pages=589–601 |doi=10.1038/nrneph.2012.186|pmid=22945490 |s2cid=34657707 }}</ref><ref>{{cite journal |last1=Jung |first1=Boris |last2=Rimmele |first2=Thomas |last3=Le Goff |first3=Charlotte |last4=Chanques |first4=Gérald |last5=Corne |first5=Philippe |last6=Jonquet |first6=Olivier |last7=Muller |first7=Laurent |last8=Lefrant |first8=Jean-Yves |last9=Guervilly |first9=Christophe |last10=Papazian |first10=Laurent |last11=Allaouchiche |first11=Bernard |last12=Jaber |first12=Samir |title=Severe metabolic or mixed acidemia on intensive care unit admission: incidence, prognosis and administration of buffer therapy. A prospective, multiple-center study |journal=Critical Care |volume=15 |issue=5 |pages=R238 |doi=10.1186/cc10487 |pmid=21995879 |pmc=3334789 |date=2011 |doi-access=free }}</ref><br>
'''Chronic:''' Highly prevalent in people with Chronic Kidney Disease: 9.4% CKD Stage 3a; 18.1% CKD Stage 3b; 31.5% CKD Stage 4 and 5 <ref>{{cite journal |last1=Inker |first1=Lesley A. |last2=Coresh |first2=Josef |last3=Levey |first3=Andrew S. |last4=Tonelli |first4=Marcello |last5=Muntner |first5=Paul |title=Estimated GFR, Albuminuria, and Complications of Chronic Kidney Disease |journal=Journal of the American Society of Nephrology |volume=22 |issue=12 |pages=2322–2331 |language=en |doi=10.1681/ASN.2010111181 |pmid=21965377 |pmc=3279937 |date=1 December 2011}}</ref>
| deaths =
| alt =
| alt =
}}
 
Line 46:
 
=== Chronic metabolic acidosis ===
Chronic metabolic acidosis has non-specific clinical symptoms but can be readily diagnosed by testing serum bicarbonate levels in patients with Chronicchronic Kidneykidney Diseasedisease (CKD) as part of a comprehensive metabolic panel. Patients with CKD Stages G3-G5G3–G5 should be routinely screened for metabolic acidosis.<ref name=":4" /><ref name=":5" />
 
==Diagnostic approach and causes==
Metabolic acidosis results in a reduced serum pH that is due to metabolic and not respiratory dysfunction. Typically the serum bicarbonate concentration will be <22 &nbsp;mEq/L, below the normal range of 22 to 29 mEq/L, the standard base will be more negative than -2 (base deficit) and the pCO<sub>2</sub> will be reduced as a result of hyperventilation in an attempt to restore the pH closer to normal. Occasionally in a mixed acid-base disorder where metabolic acidosis is not the primary disorder present, the pH may be normal or high.<ref name=":2" /> In the absence of chronic respiratory alkalosis, metabolic acidosis can be clinically diagnosed by analysis of the calculated serum bicarbonate level.
 
=== Causes ===
Generally, metabolic acidosis occurs when the body produces too much acid (e.g., lactic acidosis, see below section), there is a loss of bicarbonate from the blood, or when the kidneys are not removing enough acid from the body.
 
Chronic metabolic acidosis is most often caused by a decreased capacity of the kidneys to excrete excess acids through renal ammoniagenesis. The typical Western diet generates 75-10075–100 mEq of acid daily,<ref>{{Cite journal |last=Weaver |first=Connie M. |date=2013-05-06 |title=Potassium and Health123 |journal=Advances in Nutrition |volume=4 |issue=3 |pages=368S–377S |doi=10.3945/an.112.003533 |issn=2161-8313 |pmc=3650509 |pmid=23674806}}</ref> and individuals with normal kidney function increase the production of ammonia to get rid of this dietary acid. As kidney function declines, the tubules lose the ability to excrete excess acid, and this results in buffering of acid using serum bicarbonate, as well as bone and muscle stores.<ref>{{Cite web|url=https://www.uptodate.com/contents/pathogenesis-consequences-and-treatment-of-metabolic-acidosis-in-chronic-kidney-disease|title=Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease|last=Kovesdy|first=Csaba|website=UpToDate}}</ref>
 
There are many causes of acute metabolic acidosis, and thus it is helpful to group them by the presence or absence of a normal anion gap.<ref>{{Cite book|title=Symptom to diagnosis: an evidence-based guide|url=https://accessmedicine.mhmedical.com/book.aspx?bookID=1088|url-access=subscription|last1=Stern|first1=Scott D. C.|last2=Cifu|first2=Adam S.|last3=Altkorn|first3=Diane|isbn=9780071803441|edition= 3rd|location=New York|publisher=[[McGraw-Hill Education]]|date=2015|oclc=896866189}}</ref>
Line 75:
 
'''Normal anion gap'''{{Main|Normal anion gap acidosis}}
Causes of normal anion gap include:<ref>{{Cite book|title=The renal system: basic science and clinical conditions|date=2010|publisher=Churchill Livingstone/Elsevier|last1=Field|first1=Michael J.|last2=Pollock|first2=Carol A.|last3=Harris|first3=David C.|isbn=9780702033711|edition=2nd|location=Edinburgh|oclc=319855752|url-access=registration|url=https://archive.org/details/renalsystembasic0000fiel}}</ref>
 
* Inorganic acid addition
Line 103:
Adjunctive tests are useful in determining the aetiology of a raised anion gap metabolic acidosis including detection of an osmolar gap indicative of the presence of a toxic alcohol, measurement of serum ketones indicative of ketoacidosis and renal function tests and urinanalysis to detect renal dysfunction.
 
Elevated protein (albumin, globulins) may theoretically increase the anion gap but high levels are not usually encountered clinically. Hypoalbuminaemia, which is frequently encountered clinically, will ''mask'' an anion gap. As a rule of thumb, a decrease in serum albumin by 1G1&nbsp;G/L will decrease the anion gap by 0.25&nbsp;mmol/L
 
==Pathophysiology==
Line 118:
 
===Buffer===
The decreased bicarbonate that distinguishes metabolic acidosis is therefore due to two separate processes: the buffer (from water and carbon dioxide) and additional renal generation. The buffer reactions are: <chem display=block>H+ + HCO3- <=> H2CO3 <=> CO2 + H2O</chem>
 
The [[Henderson-HasselbalchHenderson–Hasselbalch equation]] mathematically describes the relationship between blood pH and the components of the bicarbonate buffering system: <math chem display=block>p\ce{H}=pK_\text{a}+\log_operatorname{10\mathrm{Log}}\frac{\left[\ce{HCO3^-}\right]}{\left[\ce{CO2}\right]}\text{,}</math> where {{math|''pK''<sub>a</sub>&nbsp;&approx;&nbsp; 6.1}}. In clinical practice, the concentration of {{CO2}} concentration is usualusually estimateddetermined via [[Henry's law]]: [from {{CO2}}] = 0.03 × math|''P''<sub>a{{CO2}}</sub>}}, wherethe P<sub>{{CO2}}</sub> is the [[partial pressure]] ofin {arterial blood: <math chem display=block>[\ce{CO2}}] in= arterial(0.03\text{ bloodL}^{-1}/\text{mmHg})\times P_{\text{a}\ce{CO2}}\text{.}</math>
:<chem>H+ + HCO3- <=> H2CO3 <=> CO2 + H2O</chem>
 
For example, blood gas machines usually determine bicarbonate concentrations from measured ''p''H and {{math|''P''<sub>a{{CO2}}</sub>}} values. Mathematically, the algorithm [[substitution (algebra)|substitutes]] the Henry's law formula into the Henderson-Hasselbach equation and then rearranges: <math chem display=block>\left[\ce{HCO3^-}\right]=(0.03\text{ L}^{-1}/\text{mmHg})P_{\text{a}\ce{CO2}}\cdot 10^{p\ce{H}-pK_\text{a}}</math> At [[sea level]], normal numbers might be {{math|''p''H&nbsp;&approx; 7.4}} and {{math|''P''<sub>a{{CO2}}</sub>&nbsp;&approx; 40&nbsp;mmHg}}; these then imply <math chem display=block>\begin{align}
The [[Henderson-Hasselbalch equation]] mathematically describes the relationship between blood pH and the components of the bicarbonate buffering system: <math chem display=block>p\ce{H}=pK_\text{a}+\log_{10}\frac{\left[\ce{HCO3-}\right]}{\left[\ce{CO2}\right]}</math> where ''pK''<sub>a</sub>&nbsp;&approx;&nbsp;6.1. In clinical practice, the concentration of {{CO2}} is usual estimated via [[Henry's law]]: [{{CO2}}] = 0.03 × P<sub>{{CO2}}</sub>, where P<sub>{{CO2}}</sub> is the [[partial pressure]] of {{CO2}} in arterial blood.
\left[\ce{HCO3^-}\right]&=(0.03\text{ L}^{-1}/\text{mmHg})(40\text{ mmHg})\cdot10^{7.4-6.1} \\
&=24\text{ L}^{-1}
\end{align}</math>
 
== Consequences ==
 
=== Acute metabolic acidosis ===
Acute Metabolicmetabolic Acidosisacidosis most often occurs during hospitalizations, and acute critical illnesses. It is often associated with poor prognosis, with a mortality rate as high as 57% if the pH remains untreated at 7.20.<ref name="Treatment of acute metabolic acidos">{{cite journal |last1=Kraut |first1=Jeffrey A. |last2=Madias |first2=Nicolaos E. |title=Treatment of acute metabolic acidosis: a pathophysiologic approach |journal=Nature Reviews Nephrology |date=4 September 2012 |volume=8 |issue=10 |pages=589–601 |doi=10.1038/nrneph.2012.186|pmid=22945490 |s2cid=34657707 }}</ref> At lower pH levels, acute metabolic acidosis can lead to impaired circulation and end organ function.
 
=== Chronic metabolic acidosis ===
Chronic metabolic acidosis commonly occurs in people with Chronicchronic Kidneykidney Diseasedisease (CKD) with an eGFR of less than 45 ml/min/1.73m<sup>2</sup>, most often with mild to moderate severity; however, metabolic acidosis can manifest earlier on in the course of Chronic Kidney DiseaseCKD. Multiple animal and human studies have shown that metabolic acidosis in Chronic Kidney DiseaseCKD, given its chronic nature, has a profound adverse impact on cellular function, overall contributing to high morbidities in patients.
 
The most adverse consequences of chronic metabolic acidosis in people with Chronic Kidney DiseaseCKD, and in particular, for those who have [[Kidney failure|end-stage renal disease (ESRD)]], are detrimental changes to the bones and muscles.<ref name=":1">{{Cite journal|last1=Kraut|first1=Jeffrey A.|last2=Madias|first2=Nicolaos E.|title=Adverse Effects of the Metabolic Acidosis of Chronic Kidney Disease|journal=Advances in Chronic Kidney Disease|language=en|volume=24|issue=5|pages=289–297|doi=10.1053/j.ackd.2017.06.005|pmid=29031355|year=2017}}</ref> Acid buffering leads to loss of bone density, resulting in an increased risk of bone fractures,<ref>{{Cite journal|last1=Kato|first1=Akihiko|last2=Kido|first2=Ryo|last3=Onishi|first3=Yoshihiro|last4=Kurita|first4=Noriaki|last5=Fukagawa|first5=Masafumi|last6=Akizawa|first6=Tadao|last7=Fukuhara|first7=Shunichi|date=2014|title=Association of serum bicarbonate with bone fractures in hemodialysis patients: the mineral and bone disorder outcomes study for Japanese CKD stage 5D patients (MBD-5D)|journal=Nephron Clinical Practice|volume=128|issue=1–2|pages=79–87|doi=10.1159/000365089|issn=1660-2110|pmid=25378374|s2cid=20320396}}</ref> renal osteodystrophy,<ref>{{Cite journal|last1=Lefebvre|first1=A.|last2=de Vernejoul|first2=M. C.|last3=Gueris|first3=J.|last4=Goldfarb|first4=B.|last5=Graulet|first5=A. M.|last6=Morieux|first6=C.|title=Optimal correction of acidosis changes progression of dialysis osteodystrophy|journal=Kidney International|volume=36|issue=6|pages=1112–1118|doi=10.1038/ki.1989.309|issn=0085-2538|pmid=2557481|year=1989|doi-access=free}}</ref> and bone disease;<ref name=":1" /> as well, increased protein catabolism leads to muscle wasting.<ref>{{Cite journal|last1=Hanna|first1=Ramy M.|last2=Ghobry|first2=Lena|last3=Wassef|first3=Olivia|last4=Rhee|first4=Connie M.|last5=Kalantar-Zadeh|first5=Kamyar|title=A Practical Approach to Nutrition, Protein-Energy Wasting, Sarcopenia, and Cachexia in Patients with Chronic Kidney Disease|journal=Blood Purification|volume=49|issue=1–2|language=en|pages=202–211|doi=10.1159/000504240|issn=0253-5068|pmid=31851983|year=2020|s2cid=209418220|doi-access=free}}</ref><ref>{{Cite journal|last1=Foley|first1=Robert N.|last2=Wang|first2=Changchun|last3=Ishani|first3=Areef|last4=Collins|first4=Allan J.|last5=Murray|first5=Anne M.|date=2007|title=Kidney Function and Sarcopenia in the United States General Population: NHANES III|journal=American Journal of Nephrology|language=en|volume=27|issue=3|pages=279–286|doi=10.1159/000101827|issn=0250-8095|pmid=17440263|s2cid=2847009}}</ref> Furthermore, metabolic acidosis in Chronic Kidney DiseaseCKD is also associated with a reduction in [[Renal function|eGFR]]; it is both a complication of Chronic Kidney DiseaseCKD, as well as an underlying cause of Chronic Kidney DiseaseCKD progression.<ref>{{Cite journal|last1=Shah|first1=Samir N.|last2=Abramowitz|first2=Matthew|last3=Hostetter|first3=Thomas H.|last4=Melamed|first4=Michal L.|date=2009-08-01|title=Serum bicarbonate levels and the progression of kidney disease: a cohort study|journal=American Journal of Kidney Diseases |volume=54|issue=2|pages=270–277|doi=10.1053/j.ajkd.2009.02.014|issn=1523-6838|pmc=4354889|pmid=19394734}}</ref><ref>{{Cite journal|last1=Dobre|first1=Mirela|last2=Yang|first2=Wei|last3=Chen|first3=Jing|last4=Drawz|first4=Paul|last5=Hamm|first5=L. Lee|last6=Horwitz|first6=Edward|last7=Hostetter|first7=Thomas|last8=Jaar|first8=Bernard|last9=Lora|first9=Claudia M.|last10=Nessel|first10=Lisa|last11=Ojo|first11=Akinlolu|date=2013-10-01|title=Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study|journal=American Journal of Kidney Diseases|volume=62|issue=4|pages=670–678|doi=10.1053/j.ajkd.2013.01.017|pmid=23489677|pmc=3701754|issn=0272-6386}}</ref><ref>{{Cite journal|last1=Menon|first1=Vandana|last2=Tighiouart|first2=Hocine|last3=Vaughn|first3=Nubia Smith|last4=Beck|first4=Gerald J.|last5=Kusek|first5=John W.|last6=Collins|first6=Allan J.|last7=Greene|first7=Tom|last8=Sarnak|first8=Mark J.|date=2010-11-01|title=Serum Bicarbonate and Long-term Outcomes in CKD|journal=American Journal of Kidney Diseases|volume=56|issue=5|pages=907–914|doi=10.1053/j.ajkd.2010.03.023|pmid=20605301|issn=0272-6386}}</ref><ref>{{Cite journal|last1=Raphael|first1=Kalani L.|last2=Wei|first2=Guo|last3=Baird|first3=Bradley C.|last4=Greene|first4=Tom|last5=Beddhu|first5=Srinivasan|date=2011-02-01|title=Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans|journal=Kidney International|volume=79|issue=3|pages=356–362|doi=10.1038/ki.2010.388|pmid=20962743|pmc=5241271|issn=0085-2538}}</ref>
 
==Treatment==
Line 138 ⟶ 141:
 
=== Acute metabolic acidosis ===
Bicarbonate therapy is generally administered In patients with severe acute acidemia (pH < 7.11), or with less severe acidemia (pH 7.1-71–7.2) who have severe acute kidney injury. Bicarbonate therapy is not recommended for people with less severe acidosis (pH ≥ 7.1), unless severe acute kidney injury is present. In the BICAR-ICU trial,<ref name="BICAR-ICU 2018">{{cite journal |last1=Jaber |first1=Samir |last2=Paugam |first2=Catherine |last3=Futier |first3=Emmanuel | display-authors=etal |title=Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial |journal=The Lancet |volume=392 |issue=10141 |pages=31–40 |language=en |doi=10.1016/S0140-6736(18)31080-8 |pmid=29910040 |date=2018|s2cid=49276138 |url=https://hal.umontpellier.fr/hal-01818634/file/2018%20Jaber%20et%20al.%20Sodium%20bicarbonate%20therapy.pdf }}</ref> bicarbonate therapy for maintaining a pH >7.3 had no overall effect on the composite outcome of all-cause mortality and the presence of at least one organ failure at day 7. However, amongst the sub-group of patients with severe acute kidney injury, bicarbonate therapy significantly decreased the primary composite outcome, and 28-day mortality, along with the need for [[kidney dialysis|dialysis]].
 
=== Chronic metabolic acidosis ===
For people with Chronicchronic Kidneykidney Diseasedisease (CKD), treating metabolic acidosis slows the progression of chronic kidney diseaseCKD.<ref>{{Cite journal|last1=Goraya|first1=Nimrit|last2=Wesson|first2=Donald E.|title=Clinical evidence that treatment of metabolic acidosis slows the progression of chronic kidney disease|journal=Current Opinion in Nephrology and Hypertension|language=en-US|volume=28|issue=3|pages=267–277|doi=10.1097/MNH.0000000000000491|pmid=30681417|pmc=6467553|issn=1062-4821|year=2019}}</ref> Dietary interventions for treatment of chronic metabolic acidosis include base-inducing fruits and vegetables that assist with reducing the urine net acid excretion, and increase TCO2. Recent research has also suggested that dietary protein restriction, through ketoanalogue-supplemented vegetarian very low protein diets are also a nutritionally safe option for correction of metabolic acidosis in people with Chronic Kidney DiseaseCKD.<ref>{{Cite journal|last1=Garneata|first1=Liliana|last2=Stancu|first2=Alexandra|last3=Dragomir|first3=Diana|last4=Stefan|first4=Gabriel|last5=Mircescu|first5=Gabriel|date=2016-07-01|title=Ketoanalogue-Supplemented Vegetarian Very Low–Protein Diet and CKD Progression|journal=Journal of the American Society of Nephrology|language=en|volume=27|issue=7|pages=2164–2176|doi=10.1681/ASN.2015040369|issn=1046-6673|pmid=26823552|pmc=4926970}}</ref>
 
Currently, the most commonly used treatment for chronic metabolic acidosis is oral bicarbonate. The NKF/KDOQI guidelines recommend starting treatment when serum bicarbonate levels are <22 mEq/L, in order to maintain levels ≥ 22 mEq/L.<ref name=":4">{{Cite journal|title=National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.|url=https://www.kidney.org/sites/default/files/docs/boneguidelines.pdf|journal=Am J Kidney Dis|volume=42 (Suppl 3)|pages=S1–S201}}</ref><ref name=":5">{{Cite web|url=https://kdigo.org/guidelines/ckd-evaluation-and-management/|title=CKD Evaluation and Management – KDIGO|website=kdigo.org|access-date=2019-12-31}}</ref> Studies investigating the effects of oral alkali therapy demonstrated improvements in serum bicarbonate levels, resulting in a slower decline in kidney function, and reduction in proteinuria – leading to a reduction in the risk of progressing to kidney failure. However, side effects of oral alkali therapy include gastrointestinal intolerance, worsening edema, and worsening hypertension. Furthermore, large doses of oral alkali are required to treat chronic metabolic acidosis, and the pill burden can limit adherence.<ref>{{Cite journal|last1=Chen|first1=Wei|last2=Abramowitz|first2=Matthew K.|title=Advances in management of chronic metabolic acidosis in chronic kidney disease|journal=Current Opinion in Nephrology and Hypertension|volume=28|issue=5|pages=409–416|doi=10.1097/MNH.0000000000000524|issn=1473-6543|pmc=6677263|pmid=31232712|year=2019}}</ref>